Efficacy and Safety on Prouk for STEMI Patients in China
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of rh-prouk as
pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed
as a multicenter, active controlled, single blinded study. The primary endpoint is to assess
the coronary recanalization 90 minutes after thrombolysis. The secondary endpoint is to
evaluate the mortality rate at day 30.